Palatin Technologies
Update in progressPTN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Palatin Technologies, Inc. is a biopharmaceutical company developing first‑in‑class medicines that modulate the melanocortin receptor system in the United States. Its programs include PL7737, an oral MC4R agonist in preclinical development; long‑acting MC4R peptides; Bremelanotide with Tirzepatide for obesity in Phase 2; and Bremelanotide with a PDE5 inhibitor for ED in select patients. It also develops PL9643 for dry eye and PL8177 for inflammatory bowel disease. Founded 1986, based in Monmouth Junction, NJ.
Company score
- Sentiment
- 0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!